Denali Therapeutics Inc.

NASDAQ:DNLI

15.15 (USD) • At close March 14, 2025
Bedrijfsnaam Denali Therapeutics Inc.
Symbool DNLI
Munteenheid USD
Prijs 15.15
Beurswaarde 2,200,007,250
Dividendpercentage 0%
52-weken bereik 14.01 - 33.33
Industrie Biotechnology
Sector Healthcare
CEO Dr. Ryan J. Watts Ph.D.
Website https://www.denalitherapeutics.com

An error occurred while fetching data.

Over Denali Therapeutics Inc.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.

Vergelijkbare Aandelen

Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc.

PCRX

22.87 USD

LifeStance Health Group, Inc. logo

LifeStance Health Group, Inc.

LFST

6.92 USD

STAAR Surgical Company logo

STAAR Surgical Company

STAA

17.05 USD

Telesis Bio, Inc. logo

Telesis Bio, Inc.

TBIO

0.3 USD

Roivant Sciences Ltd. logo

Roivant Sciences Ltd.

ROIV

10.66 USD

Neogen Corporation logo

Neogen Corporation

NEOG

9.05 USD

Privia Health Group, Inc. logo

Privia Health Group, Inc.

PRVA

23.75 USD

Progyny, Inc. logo

Progyny, Inc.

PGNY

20.36 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)